IKT Inhibikase Therapeutics Inc
Price (delayed)
$2.18
Market cap
$162.06M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.16
Enterprise value
$105.68M
Inhibikase is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders that arise inside and outside of the brain. Inhibikase is headquartered in Atlanta, Georgia with additional
Highlights
The company's debt has shrunk by 82% YoY and by 49% QoQ
The EPS has soared by 63% YoY and by 57% from the previous quarter
The revenue has plunged by 100% from the previous quarter and by 100% YoY
Inhibikase Therapeutics's gross profit has plunged by 100% from the previous quarter and by 100% YoY
Key stats
What are the main financial stats of IKT
Market
Valuations
Earnings
Shares outstanding
74.34M
Market cap
$162.06M
Enterprise value
$105.68M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.54
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$28.59M
Net income
-$27.52M
EBIT
-$27.52M
EBITDA
-$27.49M
Free cash flow
-$19.15M
Per share
Balance sheet
Liquidity
EPS
-$1.16
EPS diluted
-$1.16
Free cash flow per share
-$0.81
Book value per share
$1.41
Revenue per share
$0
TBVPS
$4.16
Total assets
$98.6M
Total liabilities
$3.73M
Debt
$110,517
Equity
$94.87M
Working capital
$94.72M
Debt to equity
0
Current ratio
26.37
Quick ratio
26.13
Net debt/EBITDA
2.05
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-89.6%
Return on equity
-103.6%
Return on invested capital
-246.7%
Return on capital employed
-29%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IKT stock price
How has the Inhibikase Therapeutics stock price performed over time
Intraday
4.31%
1 week
-8.79%
1 month
-5.22%
1 year
1.4%
YTD
-32.92%
QTD
-0.46%
Financial performance
How have Inhibikase Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$28.59M
Net income
-$27.52M
Gross margin
N/A
Net margin
N/A
The revenue has plunged by 100% from the previous quarter and by 100% YoY
Inhibikase Therapeutics's gross profit has plunged by 100% from the previous quarter and by 100% YoY
Inhibikase Therapeutics's net income has decreased by 45% YoY and by 41% from the previous quarter
Inhibikase Therapeutics's operating income has decreased by 42% from the previous quarter and by 42% YoY
Growth
What is Inhibikase Therapeutics's growth rate over time
Valuation
What is Inhibikase Therapeutics stock price valuation
P/E
N/A
P/B
1.54
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 63% YoY and by 57% from the previous quarter
The stock's price to book (P/B) is 18% less than its 5-year quarterly average of 1.8
The revenue has plunged by 100% from the previous quarter and by 100% YoY
Efficiency
How efficient is Inhibikase Therapeutics business performance
IKT's return on invested capital has surged by 73% since the previous quarter but it is down by 39% year-on-year
IKT's return on equity has surged by 70% since the previous quarter and by 3.6% year-on-year
The return on assets has surged by 56% since the previous quarter and by 2.4% year-on-year
Dividends
What is IKT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IKT.
Financial health
How did Inhibikase Therapeutics financials performed over time
IKT's total liabilities is down by 24% since the previous quarter but it is up by 6% year-on-year
The company's debt is 100% lower than its equity
The debt to equity has surged by 100% since the previous quarter but it has dropped by 100% year-on-year
The company's debt has shrunk by 82% YoY and by 49% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.